Primary myelofibrosis (MF) is a clonal disorder of multipotent haematopoietic progenitor cells in the bone marrow (Tefferi, 2000; Vannucchi et al, 2009) . Myelofibrosis can also occur secondary to polycythaemia vera (PV) or essential thrombocythaemia (ET) (Mesa et al, 2007; Passamonti et al, 2008) . The pathogenesis of MF involves excessive proliferation of a pluripotent stem cell clone that leads to ineffective erythropoiesis and atypical megakaryocyte hyperplasia and is accompanied by reactive bone marrow fibrosis (BMF) (Jacobson et al, 1978; Tefferi, 2000; Tefferi et al, 2001 ). This aberrant haematopoietic stem cell clone is thought to initiate BMF through release of cytokines that lead to activation and recruitment of tumour-associated fibroblasts, which, in turn, secrete oncogenic growth factors and produce an extracellular matrix (ECM; Fig 1) (Hlatky et al, 1994; Chou et al, 2003; Bhowmick et al, 2004; Orimo et al, 2005; Barry-Hamilton et al, 2010) .
Bone marrow fibrosis is accompanied by extramedullary haematopoiesis in the spleen and other organs and can be associated with disease progression and worse prognosis (Guglielmelli et al, 2016) . The Janus kinase (JAK) inhibitor, ruxolitinib, an approved drug for MF, improved spleen size, MF symptoms and overall survival (Harrison et al, , 2016 Verstovsek et al, 2012; Mesa et al, 2013) along with durable spleen volume reduction and improved overall survival for the subset of patients who continued long-term treatment (Verstovsek et al, 2016) . Although ruxolitinib did not consistently reduce BMF (Harrison et al, 2016) nor improve blood cell counts in most patients , there is evidence that for patients treated for 5 years or longer, ruxolitinib may improve or stabilize BMF (Kvasnicka et al, 2013 ). An unmet need exists for new treatments for BMF in patients with MF, which could possibly lead to an improvement of blood cell counts, particularly anaemia and thrombocytopenia, for which limited effective therapies currently exist.
Lysyl oxidase-like-2 (LOXL2), an ECM enzyme that catalyses the cross-linking of collagen and elastin, is widely expressed across many fibrotic diseases, including MF (Eliades et al, 2011; Papadantonakis et al, 2012; Tadmor et al, 2013) . LOXL2 is expressed in desmoplastic tumours, such as colorectal cancer, with no expression in the adjacent nonneoplastic areas (Fong et al, 2007) . Furthermore, LOXL2 expression is strongly associated with, and drives, the desmoplastic reaction in tumours (Papadantonakis et al, 2012) , suggesting that LOXL2 is a promising therapeutic target. Indeed, inhibiting LOXL2 reduced fibrosis in a mouse model of MF (Eliades et al, 2011) .
Simtuzumab is a non-competitive monoclonal antibody inhibitor of LOXL2 enzymatic activity that was shown to bind to both human and mouse LOXL2, block fibroblast activation, and attenuate tumour growth and the desmoplastic reaction in mouse models (Barry-Hamilton et al, 2010; Rodriguez et al, 2010) . Simtuzumab was well tolerated in patients with solid tumours (LoRusso et al, 2014) . These data suggest that simtuzumab, a humanized form of the allosteric antibody inhibitor to LOXL2, may improve BMF in patients by blocking fibroblast activation.
This phase 2 study was conducted with a 2-stage design to evaluate the effects of simtuzumab on BMF in patients with primary MF and post-PV/ET MF. Simtuzumab was evaluated alone in Stage 1 and in combination with ruxolitinib in Stage 2. (Passamonti et al, 2008 (Passamonti et al, , 2010 . Patients with low-risk disease were considered eligible if they also had symptomatic splenomegaly that was ≥10 cm below left costal margin by physical examination. Other inclusion criteria were adequate organ function, Eastern Cooperative Oncology Group performance status ≤2 and any treatment-related toxicities from prior therapies resolved to Grade ≤1. Key exclusion criteria included a known history of human immunodeficiency virus, hepatitis C or hepatitis B; the presence of any cancer within 3 years prior to enrolment; and the use of any cytotoxic chemotherapeutic agents (e.g. hydroxycarbamide), corticosteroids or immunomodulators within 2 weeks and interferon use within 4 weeks prior to study day 1.
Methods

Eligibility
This study was conducted in accordance with the International Conference on Harmonisation guideline for Good Clinical Practice and the original principles embodied in the Declaration of Helsinki. The protocol was approved by institutional review boards at each participating site prior to initiation. All patients provided written informed consent.
Study design
This was a phase 2, prospective, open-label, 2-stage trial (NCT01369498) conducted at 7 sites in the United States. The study design is shown in Fig 2. In Stage 1, patients received simtuzumab 200 or 700 mg administered intravenously (IV) over 30 min every 2 weeks for 6 infusions per 12-week cycle. These doses of simtuzumab were chosen 
Study endpoints and assessments
The primary efficacy endpoint was rate of clinical response defined by the proportion of patients with a reduction in BMF score following 24 weeks of treatment with simtuzumab. Key secondary efficacy endpoints were clinical improvements in haemoglobin, platelet count or ANC.
Clinical improvement was defined as 1 of the following: a ≥20 g/l increase in haemoglobin level from baseline and becoming transfusion independent (absence of red blood cell transfusions in the prior 8 weeks, for patients with baseline haemoglobin <100 g/l); a ≥100% increase in platelet count from baseline and an absolute platelet count of ≥50 9 10 9 /l (for patients with baseline platelet count of <50 9 10 9 /l); a ≥100% increase from baseline in ANC and an ANC of ≥0Á5 9 10 9 /l (for patients with baseline ANC of <1 9 10 9 /l).
Exploratory endpoints included spleen size reduction and overall response rate (ORR). Overall response rate was defined as the proportion of patients who achieved a CR, PR, clinical improvement in haemoglobin/platelet count/ ANC or stable disease with a reduction in BMF score. Complete remission was defined as complete resolution of disease-related symptoms (including palpable hepatosplenomegaly), haemoglobin >110 g/l, platelet count ≥100 9 10 9 /l, ANC ≥1Á0 9 10 9 /l, normal leucocyte differential and bone marrow histological remission. Partial remission required all of the CR criteria to be met, except for bone marrow histological remission.
Patients assessed the severity of their symptoms (on a scale of 0-10) using the 27-item Myelofibrosis Neoplasm Symptoms Assessment Form (MPN-SAF) questionnaire (Emanuel et al, 2012) . The MPN-SAF mean symptom score (MSS) was calculated as the average of the scales for all answered questions at each visit for each patient. If more than 10 questions were not answered at a given visit, then the MSS for that visit was considered missing. Change in MSS from baseline = (MSS at post-baseline -MSS at baseline).
Bone marrow aspirate and biopsy was performed at screening, at 3 months, 6 months and every 6 months thereafter. They included confirmation of diagnosis, assessments of marrow aspirate, reticulin stain, trichrome stain and standard cytogenetic analysis for marrow biopsy/aspirate. Blood samples were collected to determine simtuzumab serum concentration on days 1, 15, 29, 43, 57 and 71. Spleen size was assessed by physical examination (at screening) and volumetric abdominal/pelvic magnetic resonance imaging (MRI) scan (at screening, 3 months, 6 months and every 6 months thereafter). Safety was evaluated based on clinical laboratory assessments (clinical chemistry and haematology) and adverse events (AEs), coded using Medical Dictionary for Regulatory Activities (MedDRA), version 17.1 (https://www.meddra.org). Haematological assessments and serum chemistry were assessed at screening and at regular intervals throughout the study. Adverse events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03 from the National Cancer Institute (http://evs.nci.nih.gov/ ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8. 5x11.pdf).
Statistical analyses
The sample size was chosen to achieve a target of 12-27 patients in each dose level (200 or 700 mg), Stages 1 and 2 combined. Because this was a 2-stage study, the total number of patients enrolled depended on the observed efficacy during Stage 1. The trial would be stopped if the probability that an ORR of ≥ 30% would be achieved was less than 12Á5% (i.e. no responses in either the 200-mg or 700-mg group of up to 12 subjects after 2 cycles in Stage 1). The trial was to be considered a success if the probability of an ORR ≥ 30% was at least 90% (12 out of 27 responses in either 200-mg or 700-mg dose level, with Stages 1 and 2 combined) at the end of the trial.
The primary efficacy endpoint was analysed on the per protocol population, which included all randomised patients who received ≥1 dose of study medication, met the inclusion criteria for disease status (intermediate-1, intermediate-2 or high-risk disease; or had splenomegaly ≥10 cm below left costal margin), were on stable doses of ruxolitinib in phase 2 and had ≥80% adherence with simtuzumab. Safety analysis was conducted on randomised patients who received at least 1 dose of simtuzumab. Pharmacokinetic data were analysed for the safety population who had sufficient baseline and on-study measurements available for interpretation.
Descriptive statistics were used to summarise demographics, baseline characteristics and disease characteristics by treatment group. For analysing the primary efficacy endpoint, the patients without BMF scores at baseline or at week 24 were considered as non-responders and included in the denominator of the calculation of rate of response. The rate of reduction in BMF and the rate of clinical improvement in haemoglobin, platelet count and ANC were summarized as percentages, with 2-sided 90% exact confidence intervals (CIs) calculated (based on the binomial distribution). Changes in MSS over time and best change from baseline were summarized using descriptive statistics and plotted as mean (AE standard deviation [SD] ) over time by treatment stage. Descriptive statistics (sample size, mean, SD, coefficient of variation [% CV], median, first quartile, third quartile, minimum and maximum) were calculated and tabulated for serum simtuzumab concentrations per sampling time.
Results
Patient disposition
A total of 54 patients were enrolled in the study between 14 July 2011 and 17 December 2013: 24 in Stage 1 (simtuzumab monotherapy) and 30 in Stage 2 (simtuzumab + ruxolitinib). In Stage 1, there were 12 patients in each treatment group (simtuzumab 200 or 700 mg). All patients in Stage 1 discontinued from the study, most frequently due to lack of efficacy (75Á0%, Figure S1 ). One patient (8Á3%) in the 200-mg group and 2 patients (16Á7%) in the 700-mg group discontinued due to an AE. Other reasons for discontinuation in Stage 1 included investigator's discretion, withdrawal of consent and study discontinuation by the sponsor (1 patient each).
In Stage 2, 15 patients were enrolled in each treatment group (simtuzumab 200 mg + ruxolitinib or simtuzumab 700 mg + ruxolitinib, Figure S1 ). All patients in Stage 2 discontinued from the study, most commonly due to study discontinuation by the sponsor (n = 17), lack of efficacy (n = 4) or investigator's discretion (n = 4). There was 1 withdrawal due to an AE (6Á7%) in the simtuzumab 700 mg + ruxolitinib group and none in the simtuzumab 200 mg + ruxolitinib group. Other reasons for discontinuation in Stage 2 included withdrawal of consent (n = 2), death (n = 1) and disease progression (n = 1). Analyses of efficacy were performed on all enrolled patients who received at least 1 dose of study medication (per protocol set), which included 23 patients in Stage 1 (11 in the simtuzumab 200-mg group and 12 in the simtuzumab 700-mg group) and 30 patients in Stage 2 (15 per group).
Demographics and baseline characteristics were similar for both stages (Stage 1 and 2) and were relatively evenly distributed among treatment groups (Table I) . In Stage 1, the median (range) age was 71 (44-85) years, and the majority of patients were white (95Á8%). The simtuzumab 200-mg group had fewer male patients compared with simtuzumab 700 mg (50Á0% vs. 66Á7%) and a lower baseline weight and body mass index. In Stage 2, the median (range) age was 69 (43-87) years, and the majority of patients were white (90Á0%). The simtuzumab 700 mg + ruxolitinib group had a greater number of male patients than simtuzumab 200 mg + ruxolitinib (73Á3% vs. 40Á0%) and a higher baseline weight.
In both stages, each treatment group included patients with primary MF, post-PV MF, or post-ET MF (Table I) . The time since diagnosis ranged from 1 to 347 months and varied between treatment groups (Table I) . At baseline, the majority of patients in each stage had evidence of significant BMF (European Consensus on Grading BMF [Thiele & Kvasnicka, 2006 ;] scores of ≥MF-2, Table I ).
Efficacy
The efficacy results for both stages are summarized in Table II . In Stage 1, 0 patients in the simtuzumab 200-mg S. Verstovsek et al group and 2 (16Á7%, 90% CI 3Á0-43Á8) patients in the simtuzumab 700-mg group met the primary efficacy endpoint of reduction in BMF from baseline to week 24. In Stage 2, 1 (6Á7%, CI 0Á3-27Á9) patient in the simtuzumab 200 mg + ruxolitinib and 2 (13Á3%, CI 2Á4-36Á3) patients in the simtuzumab 700 mg + ruxolitinib met the primary efficacy endpoint. Similar numbers of patients had increases in BMF in both stages.
Similar results were observed for haemoglobin, platelet counts and ANC (Table II) . In Stage 1, no patient had improvements in haemoglobin at any time post-baseline. In Stage 2, 1 patient (11Á1%) in the simtuzumab 200 mg + ruxolitinib group had improved haemoglobin at some time post-baseline, but none showed improvements at week 12 or 24. Additional analysis of haemoglobin data from laboratory results demonstrated 2/9 (22Á2%) patients in the simtuzumab 200 mg + ruxolitinib group had improvements in haemoglobin at some point post-baseline, but not at week 12 or 24. Exploratory analysis of haemoglobin levels over time is shown in Fig 3 by treatment and stage. Mean change in platelet count over time is shown in Fig 4 . In Stage 1, there was no improvement in platelet count at any time post-baseline for the 8 patients who were eligible for analysis (baseline platelet count <50 9 10 9 /l, Table II ). In Stage 2, none of patients were eligible for platelet analysis. There was no clinical improvement in ANC for any patients in Stage 1 (n = 2) or Stage 2 (n = 1) who were eligible for analysis (ANC <1 9 10 9 /l, Table II ). The ORR was 7Á7% (2 out of 26 patients) in the simtuzumab 200-mg group, and 14Á8% (4 out of 27 patients) in the simtuzumab 700-mg group (Stage 1 and 2 combined, Table II ). Thus, the probability of an ORR of ≥30% was 0Á005 for 200-mg simtuzumab and 0Á047 for 700-mg simtuzumab, which did not meet the success criteria of the trial.
To explore the possibility that BMF would improve with extended treatment, BMF scores beyond 24 weeks were analysed for a subset of patients in each stage. Five patients in Stage 2 showed reduced BMF beyond 24 weeks. Patients in the simtuzumab 200 mg + ruxolitinib group had reductions in BMF at 36 weeks (2/5 patients), 60 weeks (3/5 patients) and at 72 weeks (the longest treatment duration analysed post-baseline, 1/1 patient). There was an increase in BMF for 1 patient in the simtuzumab 200 mg + ruxolitinib group at 36, 48 and 60 weeks post-baseline; and for 1 patient in the simtuzumab 700 mg + ruxolitinib group at 48 weeks postbaseline. The mean (AESD) MSS did not demonstrate a consistent pattern of improvement or decline for patients on therapy over time (Fig 5) . Of the 5 patients in the simtuzumab 200-mg group who met criteria for assessment, 1 patient had a spleen response at some time post-baseline, but there were no responses in any other treatment group (Table II) .
Pharmacokinetics
During Stage 1, mean serum simtuzumab levels appeared to increase dose proportionally following administration of 200-mg and 700-mg IV simtuzumab (Table III) . In Stage 2, ANC, absolute neutrophil count; BMF, bone marrow fibrosis; Hb, haemoglobin; RUX, ruxolitinib; SIM, simtuzumab. *One randomized patient who did not meet per-protocol analysis was excluded. †From baseline to 24 weeks. ‡Clinical improvement at any time during the 24 weeks post-baseline defined as 1 of the following: haemoglobin, minimum increase from baseline of 20 g/l and transfusion-free for ≥8 weeks with baseline <100 g/l; platelet count, ≥100% increase from baseline and absolute platelet count of ≥50 9 10 9 /l (for patients with baseline platelet count of <50 9 10 9 /l); a ≥ 100% increase from baseline in ANC and an ANC of ≥0Á5 9 10 9 /l (for patients with baseline ANC of <1 9 10 9 /l). §Overall response rate defined as the proportion of patients who achieved a complete remission, partial remission, clinical improvement in haemoglobin/platelet count/ANC or stable disease with a reduction in BMF score.
¶Response any time post-baseline (lasting for ≥8 weeks), defined as either a ≥ 50% reduction in palpable splenomegaly of a spleen that is >10 cm at baseline, or a spleen that was palpable at >5 cm at baseline and becomes not palpable. following administration of simtuzumab in combination with ruxolitinib, mean serum simtuzumab levels also appeared to be generally dose proportional between 200-mg and 700-mg IV simtuzumab. Furthermore, mean and median serum simtuzumab levels appeared to be comparable between simtuzumab monotherapy (Stage 1) and the combination with ruxolitinib (Stage 2).
Safety
In Stage 1, patients in the simtuzumab 200-mg group were exposed to a mean (SD) of 2Á3 (1Á36) cycles for a mean (SD) duration of 25Á4 (23Á81) weeks. Patients in the simtuzumab 700-mg group were exposed to 1Á8 (0Á72) cycles for a mean duration of 20Á0 (10Á64) weeks. In Stage 2, patients in the simtuzumab 200 mg + ruxolitinib group were exposed to simtuzumab for 4Á9 (1Á85) cycles for a mean duration of 56Á3 (21Á51) weeks. Patients in the simtuzumab 700 mg + ruxolitinib group were exposed to simtuzumab for 3Á4 (1Á84) cycles for a mean duration of 37Á4 (23Á30) weeks. Mean duration of exposure to ruxolitinib was 47Á7 (25Á08) weeks in the simtuzumab 200 mg + ruxolitinib group and 27Á9 (19Á96) weeks in the simtuzumab 700 mg + ruxolitinib group.
All patients in the study experienced at least 1 treatmentemergent AE during the study (not necessarily related to study drug, Table IV ). Overall, anaemia was the most common grade ≥3 AE (12Á5% and 13Á3% in Stage 1 and 2, respectively, Table IV ). The most common grade ≥3 AEs in the simtuzumab 200-mg group were febrile neutropaenia and urinary tract infection (UTI, 2 patients, 16Á7% for both). In the simtuzumab 700-mg group, 2 patients had anaemia (16Á7%). The most common grade ≥3 AEs in the simtuzumab 200-mg + ruxolitinib group were hyponatraemia (3 patients, 20Á0%) and UTI, increased alanine aminotransferase and hypertension (all 2 patients, 13Á3% for each). In the simtuzumab 700-mg + ruxolitinib group, anaemia (3 patients, 20Á0%) and thrombocytopaenia, fatigue and diarrhoea Serious AEs considered related to the treatment are shown in Table V . One patient in Stage 1 had 2 SAEs considered related to simtuzumab (pyrexia and pain in extremity, in the simtuzumab 200-mg group). In Stage 2, 1 patient had an infusion-related reaction. The infusion was stopped and vital signs were monitored, and the symptoms subsided on the same day. Fourteen days later, the patient was diagnosed with systemic mastocytosis, which was considered by the investigator to be the likely cause of the reaction, with the infusion considered a probable precipitating factor.
There were 2 deaths in the study. One death in Stage 1 (simtuzumab 700-mg) was reported by the investigator as being caused by disease progression, with multiple brain lesions surrounded by vasogenic oedema revealed by MRI, and considered, in the setting of a myeloproliferative disorder, to be possible granulocytic sarcomas. In Stage 2, 1 patient died due to cerebral haemorrhage and had experienced pulmonary embolism prior to receiving the study drug.
Discussion
This study used a novel therapeutic approach to address an unmet need. The results of this study suggest that simtuzumab treatment either alone or in combination with ruxolitinib would have limited effectiveness in patients with primary MF or post-PV/ET MF. Simtuzumab was well tolerated but did not reliably reduce BMF at 24 weeks and did not meet the pre-specified desired response of ≥12 responses in ORR out of 27 subjects for either 200-mg or 700-mg dose level (Stage 1 and 2 combined). Bone marrow fibrosis decreased in some patients and increased in others, possibly due to sampling variability. Although there was a numerical improvement in MSS and haemoglobin in some patients in Stage 2 (Figs 3 and 5), there was insufficient evidence that simtuzumab was effective during the 24-week study. It is possible that longer simtuzumab treatment periods would be effective in patients with less advanced MF. Preclinical findings were promising with simtuzumab. Simtuzumab demonstrated LOXL2 inhibition and reduced LOXL2-mediated changes to the ECM in vitro and reduced fibroblast activation and fibrosis in mouse models of tumour formation, liver fibrosis and pulmonary fibrosis (BarryHamilton et al, 2010) . Concomitant with these effects were reductions in associated growth factors and cytokines.
In this clinical study, serum simtuzumab levels appeared to increase in a dose-dependent manner, with comparable levels for both the monotherapy and in combination with ruxolitinib. However, the kinetics of simtuzumab treatment and bone marrow remodelling are not well understood, raising the possibility that a longer treatment schedule would improve patient response. Five patients in Stage 2 did show improvements in BMF at time points well beyond week 24, implying that with a larger sample size, a longer treatment period may yield different results. Improvements in haemoglobin showed a similar trend. Likewise, this study included 54 patients with a known diagnosis of MF for a mean period of 20-56 weeks. It is possible that treatment of earlier stage disease may be more likely to affect marrow fibrosis. Alternatively, a different drug combination or sequencing of therapy may be required to improve response.
Ultimately, the complexity of the MF pathogenesis may explain the lack of efficacy of simtuzumab, which targets a specific component of the disease process. In addition, it is possible that efficacy of simtuzumab, or other LOXL2 inhibitors, may differ for organ fibrosis compared with myelofibrosis or bone marrow fibrosis, given the different underlying aetiologies. Further studies of simtuzumab for MF are not planned, but clinical evaluations of other antifibrotic agents are underway. 
